Impacts of HIV-1 resistance mutations associated with nucleoside reverse transcriptase inhibitors on viral fitness.
- Author:
Qian ZHOU
1
;
Ling-Jie LIAO
;
Han-Ju HUANG
Author Information
1. State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China. ftts77@163.com
- Publication Type:Journal Article
- MeSH:
Animals;
Drug Resistance, Viral;
HIV Infections;
drug therapy;
virology;
HIV Reverse Transcriptase;
antagonists & inhibitors;
genetics;
metabolism;
HIV-1;
drug effects;
enzymology;
genetics;
physiology;
Humans;
Mutation;
Nucleosides;
therapeutic use;
Reverse Transcriptase Inhibitors;
therapeutic use
- From:
Chinese Journal of Virology
2012;28(3):291-296
- CountryChina
- Language:Chinese
-
Abstract:
Nucleoside reverse transcriptase inhibitors which act as a major component of highly active antiretroviral therapy regimens are widely used in treatment of Acquired Immune Deficiency Syndrome. However, the emergence of drug-resistant variants of HIV-1 severely limits the effectiveness of these drugs. Many drug resistance mutations confer a fitness cost, which can be partially overcome by compensatory mutations or other molecular mechanisms. This review focuses on the impacts of resistance mutations emerging during treatment with nucleoside reverse transcriptase inhibitors on viral fitness, and inter actions between these mutations.
